Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children

Report of 2 cases

Restricted access

Convection-enhanced delivery (CED) for the treatment of malignant gliomas is a technique that can deliver chemotherapeutic agents directly into the tumor and the surrounding interstitium through sustained, low-grade positive-pressure infusion. This allows for high local concentrations of drug within the tumor while minimizing systemic levels that often lead to dose-limiting toxicity. Diffuse intrinsic pontine gliomas (DIPGs) are universally fatal childhood tumors for which there is currently no effective treatment. In this report the authors describe CED of the topoisomerase inhibitor topotecan for the treatment of DIPG in 2 children.

As part of a pilot feasibility study, the authors treated 2 pediatric patients with DIPG. Stereotactic biopsy with frozen section confirmation of glial tumor was followed by placement of bilateral catheters for CED of topotecan during the same procedure. The first patient underwent CED 210 days after initial diagnosis, after radiation therapy and at the time of tumor recurrence, with a total dose of 0.403 mg in 6.04 ml over 100 hours. Her Karnofsky Performance Status (KPS) score was 60 before CED and 50 posttreatment. Serial MRI initially demonstrated a modest reduction in tumor size and edema, but the tumor progressed and the patient died 49 days after treatment. The second patient was treated 24 days after the initial diagnosis prior to radiation with a total dose of 0.284 mg in 5.30 ml over 100 hours. Her KPS score was 70 before CED and 50 posttreatment. Serial MRI similarly demonstrated an initial modest reduction in tumor size. The patient subsequently underwent fractionated radiation therapy, but the tumor progressed and she died 120 days after treatment.

Topotecan delivered by prolonged CED into the brainstem in children with DIPG is technically feasible. In both patients, high infusion rates (> 0.12 ml/hr) and high infusion volumes (> 2.8 ml) resulted in new neurological deficits and reduction in the KPS score, but lower infusion rates (< 0.04 ml/hr) were well tolerated. While serial MRI showed moderate treatment effect, CED did not prolong survival in these 2 patients. More studies are needed to improve patient selection and determine the optimal flow rates for CED of chemotherapeutic agents into DIPG to maximize safety and efficacy. Clinical trial registration no.: NCT00324844.

Abbreviations used in this paper:CED = convection-enhanced delivery; CN = cranial nerve; DIPG = diffuse intrinsic pontine glioma; KPS = Karnofsky Performance Status.

Article Information

Address correspondence to: Richard C. E. Anderson, M.D., The Neurological Institute, 710 West 168th Street, Room 213, New York, New York 10032. email: rca24@columbia.edu.

Please include this information when citing this paper: published online December 14, 2012; DOI: 10.3171/2012.10.PEDS12142.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Artist's rendering of CED. Drawing superimposed on an axial T1-weighted MR image showing bilateral catheters stereotactically placed through the cerebellar peduncles into the brainstem of a patient with a DIPG. Catheters are placed into the tumor with the tips approximately 1 cm apart, avoiding the fourth ventricle to minimize loss of drug to CSF. Catheters are tunneled subcutaneously to prevent migration and CSF leakage. Drug is distributed throughout the tumor via convection (yellow shading). Inset depicts sagittal orientation of patient with catheters in place.

  • View in gallery

    Case 1. Axial MR images. A and B: T2-weighted (A) and contrast-enhanced T1-weighted (B) images obtained at the time of diagnosis showing enlargement of the pons without contrast enhancement. C: Contrast-enhanced T1-weighted image obtained after radiation treatment at the time of recurrence showing new patchy enhancement. D: FLAIR image obtained immediately after surgery demonstrating bilateral catheters within the tumor. E and F: FLAIR (E) and contrast-enhanced T1-weighted (F) images obtained after treatment (6.04 ml infusion volume) showing effects of drug infusion within the tumor. G and H: T2-weighted (G) and contrast-enhanced T1-weighted (H) images obtained 1 month posttreatment demonstrating tumor progression.

  • View in gallery

    Case 2. Axial MR images. A and B: Preoperative T2-weighted (A) and contrast-enhanced T1-weighted (B) images showing enlargement of the pons with 2 small areas of mild contrast enhancement. C: T1-weighted image obtained immediately after surgery demonstrating bilateral catheters within the tumor. D and E: T2-weighted images obtained mid-treatment (3.09 ml infusion volume [D]) and immediately posttreatment (5.30 ml total infusion volume [E]) showing increasing area of drug distribution within the tumor. F: Contrast-enhanced T1-weighted image obtained 1 month after treatment demonstrating stable tumor. G and H: T2-weighted (G) and contrast-enhanced T1-weighted (H) images obtained nearly 4 months posttreatment demonstrating tumor progression.

  • View in gallery

    Case 2. Results of histological and immunohistochemical analysis of recurrent tumor at autopsy showing tumor progression. A: Hemotoxylin and eosin staining of the tumor in the pons showing the histological features of glioblastoma, with marked nuclear pleomorphism and areas of pseudopallisading necrosis (N). B and C: Immunoperoxidase staining for p53 showing strong nuclear staining (brown) in a subset of the tumor cells (B) and scattered p53+ tumor cells invading the cerebellar cortex (C). Original magnification × 100.

References

1

Albright ALPrice RAGuthkelch AN: Brain stem gliomas of children. A clinicopathological study. Cancer 52:231323191983

2

Allen JCSiffert J: Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 24:981021996

3

Bobo RHLaske DWAkbasak AMorrison PFDedrick RLOldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:207620801994

4

Bruce JNFalavigna AJohnson JPHall JSBirch BDYoon JT: Intracerebral clysis in a rat glioma model. Neurosurgery 46:6836912000

5

Bruce JNFine RLCanoll PYun JKennedy BCRosenfeld SS: Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69:127212802011

6

Frazier JLLee JThomale UWNoggle JCCohen KJJallo GI: Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. A review. J Neurosurg Pediatr 3:2592692009

7

Friedman HSKerby TFields SZilisch JEGraden DMcLendon RE: Topotecan treatment of adults with primary malignant glioma. Cancer 85:116011651999

8

Gerstner ERFine RL: Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25:230623122007

9

Groothuis DRBenalcazar HAllen CVWise RMDills CDobrescu C: Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 856:2812902000

10

Hargrave DBartels UBouffet E: Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:2412482006

11

Iyer RRButman JAWalbridge SGai NDHeiss JDLonser RR: Tracking accuracy of T2- and diffusion-weighted magnetic resonance imaging for infusate distribution by convection-enhanced delivery. Laboratory investigation. J Neurosurg 115:4744802011

12

Kaiser MGParsa ATFine RLHall JSChakrabarti IBruce JN: Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47:139113992000

13

Khatua SMoore KRVats TSKestle JR: Diffuse intrinsic pontine glioma-current status and future strategies. Childs Nerv Syst 27:139113972011

14

Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:1051112003

15

Langer R: New methods of drug delivery. Science 249:152715331990

16

Laske DWYoule RJOldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:136213681997

17

Lonser RRWarren KEButman JAQuezado ZRobison RAWalbridge S: Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 107:1901972007

18

Morrison PFChen MYChadwick RSLonser RROldfield EH: Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 277:R1218R12291999

19

Murad GJWalbridge SMorrison PFGarmestani KDegen JWBrechbiel MW: Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res 12:314531512006

20

Murad GJWalbridge SMorrison PFSzerlip NButman JAOldfield EH: Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg 106:3513562007

21

Occhiogrosso GEdgar MASandberg DISouweidane MM: Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery 52:3883942003

22

Pardridge WM: Drug delivery to the brain. J Cereb Blood Flow Metab 17:7137311997

23

Patel SJShapiro WRLaske DWJensen RLAsher ALWessels BW: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:124312532005

24

Pierre-Kahn AHirsch JFVinchon MPayan CSainte-Rose CRenier D: Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg 79:8458521993

25

Pöpperl GGoldbrunner RGildehaus FJKreth FWTanner PHoltmannspötter M: O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32:101810252005

26

Rand RWKreitman RJPatronas NVarricchio FPastan IPuri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:215721652000

27

Saito RSonoda YKumabe TNagamatsu KWatanabe MTominaga T: Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride. Case report. J Neurosurg Pediatr 7:5225262011

28

Sampson JHAkabani GArcher GEBigner DDBerger MSFriedman AH: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27352003

29

Sandberg DIEdgar MASouweidane MM: Convection-enhanced delivery into the rat brainstem. J Neurosurg 96:8858912002

30

Thomale UWTyler BRenard VDorfman BChacko VPCarson BS: Neurological grading, survival, MR imaging, and histological evaluation in the rat brainstem glioma model. Childs Nerv Syst 25:4334412009

31

Thomale UWTyler BRenard VMDorfman BGuarnieri MHaberl HE: Local chemotherapy in the rat brainstem with multiple catheters: a feasibility study. Childs Nerv Syst 25:21282009

32

Voges JReszka RGossmann ADittmar CRichter RGarlip G: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54:4794872003

33

Walker DAPunt JASokal M: Clinical management of brain stem glioma. Arch Dis Child 80:5585641999

34

Weber FWFloeth FAsher ABucholz RBerger MPrados M: Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88:931032003

35

Yang WBarth RFWu GBandyopadhyaya AKThirumamagal BTTjarks W: Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot 61:9819852004

36

Yin DRichardson RMFiandaca MSBringas JForsayeth JBerger MS: Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. Laboratory investigation. J Neurosurg 113:2402482010

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 55 55 17
Full Text Views 120 120 28
PDF Downloads 112 112 7
EPUB Downloads 0 0 0

PubMed

Google Scholar